• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

News

Recipharm to develop two inhalation formulations for Transpire Bio

Florida-based startup Transpire Bio announced that it has signed an agreement with Recipharm for development of two inhaled candidates, TRB-1 and TRB-2, for the treatment of asthma and COPD. The company says that the two generic MDIs are "intended for advanced markets." Transpire CEO Xian-Ming Zeng said, "Our mission is to improve access to important, life-saving … [Read more...] about Recipharm to develop two inhalation formulations for Transpire Bio

VisionHealth says Boehringer Ingelheim to cooperate on distribution of the Kata inhaler training app in Germany

German digital health company VisionHealth has announced that it will "cooperate on distribution of inhalation platform Kata" with Boehringer Ingelheim in Germany. The Kata app uses artificial intelligence and augmented reality technology in conjunction with the patient's smartphone camera to provide interactive inhaler use coaching. The company says that the app can … [Read more...] about VisionHealth says Boehringer Ingelheim to cooperate on distribution of the Kata inhaler training app in Germany

TFF Pharmaceuticals expands with new R&D facility

TFF Pharmaceuticals announced that it has leased a new 3,500+ square foot R&D facility in Austin, Texas, USA, that will house additional lab space, as well as equipment for the production of preclinical supplies, significantly expanding the company's capabilities. TFF also said that it will continue its relationship with the University of Texas at Austin, where … [Read more...] about TFF Pharmaceuticals expands with new R&D facility

Theravance, Innoviva selling Trelegy Ellipta royalty interests to Royalty Pharma

According to Theravance Biopharma, the company is selling its stake in Theravance Respiratory Company (TRC), which received royalties from sales of GSK's Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI. The deal with Royalty Pharma is worth up to $1.5 billion, including $1.1 billion up front, the company said. Theravance Biopharma owns 85% of TRC; … [Read more...] about Theravance, Innoviva selling Trelegy Ellipta royalty interests to Royalty Pharma

Glenmark and SaNOtize publish positive results from Phase 3 trial of nitric oxide nasal spray for COVID-19

Glenmark Pharmaceuticals and SaNOtize have announced the publication of results from a Phase 3 clinical trial of NONS nitric oxide nasal spray for the treatment of COVID-19 in The Lancet Regional Health Southeast Asia. SaNOtize announced initiation of the Phase 3 trial in June 2021, and Glenmark announced in August 2021 that it had acquired the rights to NONS in India … [Read more...] about Glenmark and SaNOtize publish positive results from Phase 3 trial of nitric oxide nasal spray for COVID-19

Pulmatrix initiates Phase 1 trial of PUR3100 inhaled dry powder DHE

Pulmatrix said that the first subjects have been dosed in a Phase 1 trial of the company's PUR3100 dry powder dihydroergotamine (DHE), which is based on Pulmatrix's iSPERSE particle engineering platform. The company announced in March 2021 that it intended to develop the PUR3100 DPI for the treatment of migraines. The Phase 1 trial is expected to enroll 24 healthy … [Read more...] about Pulmatrix initiates Phase 1 trial of PUR3100 inhaled dry powder DHE

NurExone partners with Polyrizon for development of intranasal therapy for spinal cord injuries

Israeli startup NurExone Biologic has announced that it will pay Israeli nasal delivery specialist Polyrizon a total of up to $3,350,000 for development of an intranasal formulation of NurExone's ExoTherapy, exosomes loaded with modified siRNA sequences for the treatment of traumatic spinal cord injuries. The formulation will be based on Polyrizon's Trap and Target … [Read more...] about NurExone partners with Polyrizon for development of intranasal therapy for spinal cord injuries

Bayer launches Astepro Allergy nasal spray in the US

Bayer said that its Astepro Allergy azelastine nasal spray is now available over the counter in US retail stores for the treatment of respiratory allergy symptoms in people aged 6 and older. The FDA approved Astepro Allergy for nonprescription use in June 2021. Bayer Consumer Health US VP and General Manager of Upper Respiratory Catherine Vennat said, "At Bayer, … [Read more...] about Bayer launches Astepro Allergy nasal spray in the US

RS BioTherapeutics reports positive preclinical results for its inhaled CBDa

US-based startup RS BioTherapeutics has announced that a proof of concept study demonstrated that its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) reduced but did not eliminate cytokines when dosed intranasally at 1 mg/kg in a mouse model of pulmonary inflammation. The study was conducted by researchers at Marshall University. RS BioTherapeutics licensed the … [Read more...] about RS BioTherapeutics reports positive preclinical results for its inhaled CBDa

Meissa Vaccines names Frank Glavin as CEO

Intranasal vaccine developer Meissa Vaccines has announced that Martin Moore is stepping down as the company's CEO and Frank Glavin has joined the company as the new Chief Executive Officer. Moore will stay with Meissa as Chief Scientific Officer. Glavin was most recently CEO of Orphan Technologies and was previously Head of Neovii Biotech North America. Meissa … [Read more...] about Meissa Vaccines names Frank Glavin as CEO

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 76
  • Page 77
  • Page 78
  • Page 79
  • Page 80
  • Interim pages omitted …
  • Page 416
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews